Androgenetic alopecia (AGA) is a common nonscarring hair loss condition that affects both men and women, often resulting in psychological distress and reduced quality of life. AGA pathogenesis involves genetic predisposition and androgen influence, primarily dihydrotestosterone (DHT), which leads to hair follicle miniaturization and progressive hair thinning. AGA remains challenging to manage due to its chronic progression and the combined influence of genetic and environmental factors. Topical minoxidil and oral finasteride are the most widely used treatments for AGA, addressing follicular miniaturization. However, their reliance on long-term use and potential for side effects or inconvenience has prompted increasing interest in alternative therapies. The mainstream of current AGA treatment can be categorized into androgen-targeting and non-androgen-targeting approaches. Finasteride and dutasteride, both 5-α-reductase inhibitors that reduce DHT levels in hair follicles, are key androgen-targeting treatments, with newer formulations like topical and injectable options emerging alongside traditional oral forms. Topical minoxidil remains central to non-androgen-targeted AGA treatments, though growing evidence supports the efficacy and safety of its low-dose oral form. Additionally, therapies like low-level light therapy, platelet-rich plasma, and exosome treatments are being explored. Recently, therapies targeting the androgen receptor, including small interfering RNA-based approaches, have been developed and are currently in clinical trial stages, offering innovative potential for AGA treatment. This review explores current and emerging treatments for AGA, addressing both androgen-targeted and non-androgen-targeted approaches with an emphasis on their mechanisms, efficacy, and safety. It ultimately aims to provide a comprehensive update on the latest advancements in AGA management.

Androgenetic alopecia (AGA) is the most common type of baldness, characterized by progressive miniaturization of the hair follicle and eventually atrophy. Both genetic and androgenic factors play definite roles in the pathophysiology of the disease, including androgens and growth factors, which induce a crosstalk between the dermal papilla and the hair follicle cells. The goal of AGA treatments is to prevent the hair miniaturization process; however, currently there are only two FDA-approved medications to treat AGA: topical Minoxidil (5% and 2%) for men and women, and oral Finasteride (1 mg tablets-Proscar and Propecia) for men. Nevertheless, these are costly, require lifelong treatment, and may have side effects. Thus, there have been many attempts to develop drugs that can harness the mechanisms controlling the pathogenesis of AGA. These pharmacological therapies might achieve more targeted and effective treatment for the disease. In this review, we present various treatments that have demonstrated their ability to induce hair growth by controlling the pathophysiological mechanisms involved in the development of AGA. Interestingly, treatment by a combination of some drugs has resulted in better outcomes than each of the drugs alone, hence demonstrating the advantage of activating different molecular mechanisms simultaneously.

Male Pattern Hair Loss (MPHL) is a subset of androgenetic alopecia and represents the most prevalent form of hair loss in men, whose prevalence increases significantly with age worldwide. It is caused mainly by hormonal changes, especially high levels of dihydrotestosterone, which causes miniaturization of hair follicles and progressive thinning of hair. This longitudinal study investigates the complex relationship between hormonal changes and MPHL development over a period of three years, offering an extensive examination of androgen activity, stress-related hormones, and their influence on hair follicle biology. A total of 120 participants with a diagnosis of early-stage MPHL were assigned to one of three groups: finasteride treatment, placebo, and control. Serum levels of DHT, testosterone, and cortisol were measured biannually, while hair density and follicular changes were monitored using advanced scalp imaging techniques. Participants also self-reported their experiences related to treatment efficacy and psychosocial impacts. The findings revealed a significant reduction in DHT levels among finasteride-treated participants, correlating with improved hair density and partial reversal of follicular miniaturization. In contrast, placebo and control groups showed a steady progression of hair loss, confirming the critical role of DHT in MPHL. While finasteride was effective, its side effects, such as reduced libido and fatigue, emphasized the need for safer, long-term therap

Androgenetic alopecia (AGA) is a type of alopecia non sikatrik that most often occur, especially in men. AGA is hereditary baldness and form distinctive patterns. Causes related to AGA estimated serum androgen levels, especially 5-?-dehydrotestosterone (DHT), which can lead to miniaturization of the hair follicle. Finasteride is one of drugs that proven effective in treating hair loss caused by AGA. Finasteride is a 4-azasteroid components that are competitive and specific inhibitor of the enzyme 5-?-reductase type II, an enzyme that converts testosteron into intracellular DHT. By inhibiting the enzyme 5-?-reductase type II, conversion of testosteron to DHT inhibited, thereby causing a significant decrease in serum and tissue DHT concentrations. The use of finasteride 1 mg per day proven to effectively treat AGA in men.

Androgenetic alopecia (AGA) is a type of alopecia non sikatrik that most often occur, especially in men. AGA is hereditary baldness and form distinctive patterns. Causes related to AGA estimated serum androgen levels, especially 5-?-dehydrotestosterone (DHT), which can lead to miniaturization of the hair follicle. Finasteride is one of drugs that proven effective in treating hair loss caused by AGA. Finasteride is a 4-azasteroid components that are competitive and specific inhibitor of the enzyme 5-?-reductase type II, an enzyme that converts testosteron into intracellular DHT. By inhibiting the enzyme 5-?-reductase type II, conversion of testosteron to DHT inhibited, thereby causing a significant decrease in serum and tissue DHT concentrations. The use of finasteride 1 mg per day proven to effectively treat AGA in men.

Androgenic alopecia (AGA) is associated with an increased production of 5α-dihydrotestosterone (DHT) by steroid-5α-reductase (5α-R). Crude extracts from Avicennia marina (AM) and its active constituent, avicequinone C (AC), can inhibit 5α-R. We have, herein, explored the potential use of the AM extract and of AC as anti-AGA agents. To this end, we employed human dermal papilla cells (DPCs) isolated from AGA patients’ hair that express 5α-R type-1 as well as the androgenic receptor (AR) at high levels. Our in vitro experiments revealed that the AM extract (10 μg/mL) and the AC (10 μM) exhibit m

males is unlikely to elevate DHT, which is one cause of male pattern baldness. Whether sleep deprivation can cause hair loss by some other mechanism is Pattern hair loss, also known as androgenetic alopecia, is a hair loss condition that primarily affects the top and front of the scalp. In male-pattern hair loss, the hair loss typically presents itself as either a receding front hairline, loss of hair on the crown and vertex of the scalp, or a combination of both. Female-pattern hair loss typically presents as a diffuse thinning of the hair acros Decrease in testosterone Decrease in serum DHT and 5-alpha reductase Decrease 3AAG, a peripheral marker of DHT metabolism Increase in SHBG Decrease in androgen receptors, 5-alpha reductase type I and II activity, and aromatase in the scalp This decrease in androgens and androgen receptors, and the increase in SHBG, are opposite to the increase in androgenic alopecia with aging. This is not intuitive, as testosterone and its peripheral metabolite, DHT, accelerate hair loss, and SHBG is thought to be protective. The ratio of T/SHBG, DHT/SHBG decreases by as much as 80% by age 80, in numeric parallel to hair loss, and approximates the pharmacology of antiandrogens such as finasteride. Free testosterone decreases in men by age 80 to levels double that of a woman at age 20. About 30% of the normal male testosterone level, the approximate level in females, is not enough to induce alopecia; 60%, closer to the amount found in elderly men, is sufficient. The testicular secretion of testosterone perhaps "sets the stage" for androgenic alopecia as a multifactorial diathesis stress model, related to hormonal…

Currently, the predominant hypothesis explains androgenetic alopecia (AGA) as a process reliant upon affected follicles being individually programmed to accumulate dihydrotestosterone (DHT), which then causes progressive follicular miniaturisation. The goal of this paper is to suggest that such miniaturisation may result from an exaggeration of the bone remodelling process causing a reduction in blood supply to the capillary network within the affected region. The bones of the human skull continue to grow during adulthood and observations made of those with AGA suggest that such growth may be responsible for the development of this condition. Studies of human cranial anatomy indicate that frontal and parietal bone growth can account for the development of the male pattern baldness (MPB) profile and the variations that can occur in the rate and location of hair loss. Steroid hormones such as DHT promote facial and body hair growth. Logically, this suggests that DHT should stimulate hair growth within the MPB region and not hair loss. However, DHT also has an anabolic effect on bone formation, and it is hypothesised that this stimulation of bone growth will overwhelm the hair growth promoting effects of DHT. Androgen receptor sites, 5-alpha-reductase (5alpha-R) and DHT have all been associated with AGA, but they also exist within numerous types of bone cells. DHT will stimulate the proliferation of osteoblast cells and the formation of new bone. Verification of this hypothesis

Polycystic ovary syndrome (PCOS) is a multifaceted endocrine-metabolic disorder in which androgenetic alopecia (AGA) serves as a prominent clinical marker of profound systemic dysregulation, extending beyond simple hyperandrogenism. This condition imposes a significant psychosocial burden on affected women, yet its complete pathophysiology remains incompletely understood, leading to therapeutic plateaus. This review advances the central hypothesis that alopecia in PCOS results from a synergistic failure of local follicular metabolic signaling and genetic predisposition. This framework posits that the hair follicle in susceptible individuals is a site of intrinsic vulnerability where systemic insults, principally insulin resistance and chronic low-grade inflammation, converge with specific gene polymorphisms. This local pathology both amplifies and is amplified by systemic hyperandrogenism, rendering androgen action a necessary but insufficient component of the complete pathophysiological cascade. This integrated perspective recontextualizes the roles of insulin, inflammatory mediators, and genetic variants as direct effectors of follicular distress, not merely as upstream triggers of androgen excess. We critically synthesize the evidence supporting this model, examining the intricate intersections of systemic hormone bioavailability, local androgen conversion, follicular bioenergetics, and genetic susceptibility. Furthermore, we provide an evidence-based, mechanistically organized framework for the management of PCOS-associated alopecia, evaluating therapeutic modalities based on their targeted action within this complex network. A deeper, systems-level understanding of this interplay is essential for moving beyond current therapeutic limitations and developing personalized management strategies that address the complete pathophysiological axis, ultimately improving both cutaneous and long-term systemic health outcomes for women with PCOS.

Intracrinology refers to the local synthesis, activation, and inactivation of sex steroids within peripheral tissues from precursor hormones such as dehydroepiandrosterone (DHEA), androstenedione, and testosterone (T). This process occurs largely independent of circulating hormone levels. With aging, declining adrenal and gonadal androgens create tissue-specific hormone imbalances that contribute to common symptoms in both men and women, including loss of muscle and bone mass, reduced libido, mood disturbances, low energy, and increased body fat. Conventional testosterone replacement therapy (TRT) guidelines focus on restoring serum testosterone to mid- or upper-normal ranges for young men, or to premenopausal levels in women, to avoid pharmacologic dosing. However, these serum-centric approaches fail to account for the critical role of intracrine production. In peripheral tissues, most bioactive testosterone, dihydrotestosterone (DHT) via 5α-reductase, and estradiol (E2) via aromatase are produced locally from adrenal precursors rather than from circulating testosterone alone. Continuous-release subcutaneous testosterone pellet therapy delivers stable physiologic levels of testosterone for 3-6 months. This provides a consistent substrate that allows tissues to produce DHT and E2 on demand, according to local enzyme activity, without the peaks and troughs associated with gels, injections, or oral formulations. The result is an enzyme-aware, symptom-driven model that prioritizes clinical symptom relief, individual enzyme profiles, and side effect patterns over strict serum targets. This narrative review explores the roles of steroidogenic enzymes across organ systems, the tissue-specific effects of testosterone, DHT, and estradiol, strategies for managing conversion imbalances (including adjunctive aromatase and 5α-reductase inhibitors), the limitations of serum estradiol monitoring, and observational evidence supporting higher steady-state testosterone levels for effective intracrine restoration in aging populations. While promising for individualized hormone optimization with acceptable safety in monitored patients, this approach requires validation through large-scale randomized controlled trials.

Excluding clinically relevant borderline values, only 6.4% of patients were without any abnormalities. The incidence rate of pathologic parameters was as follows: FT in % = 52%, Fe = 42%, PRL = 34%, E2 = 34%, FT in pg = 29%, DHT = 28%, SHBG = 26%, TSH = 20.8%, DS = 19%, T = 14%, 17P = 11%, Fo = 7%, A = 6%, F = 6%, B12 = 5%. Group and individual case analyses revealed significant correlations between (1) the levels of the various androgens, PRL and TSH and (2) the E2, SHBG and FT values; these, in turn, were correlated to (3) the occurrence of certain bleeding anomalies (amount, duration, interval) and corresponding ferritin deficiency. Therapy was directed at normalizing the disturbed estrogen-androgen-balance. Using low-dose antiandrogens, estrogens, prolactin suppressants, corticoids, iron-II-preparations as well as estrogen-containing hair lotions hair loss was arrested in 74 of 104 treated women, while regrowth of hair was accomplished in 16 patients. 14 women did not respond to therapy. Published in Geburtshilfe und Frauenheilkunde (1988)

This study examines the synergistic effects of extracts from Rhynchosia nulubilis (RN) and Polygonum multiflorum (PM) on the proliferation of human dermal papilla cells (hDPCs) and the alleviation of testosterone-induced cytotoxicity. Human dermal papilla cells (hDPCs) were treated with varying concentrations of RN and PM extracts, administered both individually and in multiple combinations at different ratios. The findings indicated that a 4:1 combination of RN and PM extracts significantly enhanced hDPC proliferation relative to the individual extracts, particularly in the presence of testos

have shown DHT is not the final cause of hair loss, DHT causes the follicle to stop growing hair (known … of Hair Loss. Until a short time ago researchers thought that DHT was the main cause of hair loss. Further … of hair loss has shown DHT to be an important link in the chain of events that lead to hair loss, but